Literature DB >> 11813066

QBC for the diagnosis of human and canine american visceral leishmaniasis: preliminary data.

D B Liarte1, I L Mendonça, F C Luz, E A Abreu, G W Mello, T J Farias, A F Ferreira, M A Millington, C H Costa.   

Abstract

"Quantitative Buffy Coat" (QBC) is a direct and fast fluorescent method used for the identification of blood parasites. Since Leishmania chagasi circulates in blood, we decided to test it in American visceral leishmaniasis (AVL). Bone marrow (BM) and peripheral blood (PB) of 49 persons and PB of 31 dogs were analyzed. QBC was positive in BM of 11/11 patients with AVL and in 1/6 patients with other diseases. Amastigotes were identified in PB of 18/22 patients with AVL and in none without AVL. The test was positive in 30 out of the 31 seropositive dogs and in 28/28 dogs with Leishmania identified in other tissues. QBC is a promising method for diagnosis of human AVL, and possibly for the exam of PB of patients with AVL/AIDS, for the control of the cure and for the identification of asymptomatic carriers. Because it is fast and easy to collect and execute, QBC should be evaluated for programs of reservoir control.

Entities:  

Mesh:

Year:  2001        PMID: 11813066     DOI: 10.1590/s0037-86822001000600013

Source DB:  PubMed          Journal:  Rev Soc Bras Med Trop        ISSN: 0037-8682            Impact factor:   1.581


  8 in total

1.  Detection of pneumococcemia by quantitative buffy coat analysis.

Authors:  P C Wever; E R Heddema; M G A van Vonderen; J T M van der Meer; M D de Jong; T van Gool
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-06-24       Impact factor: 3.267

2.  Leishmania infection impairs beta 1-integrin function and chemokine receptor expression in mononuclear phagocytes.

Authors:  Nathanael F Pinheiro; Micely D R Hermida; Mariana P Macedo; José Mengel; Andre Bafica; Washington L C dos-Santos
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

3.  IDENTIFICATION OF CANINE VISCERAL LEISHMANIASIS IN A PREVIOUSLY UNAFFECTED AREA BY CONVENTIONAL DIAGNOSTIC TECHNIQUES AND CELL-BLOCK FIXATION.

Authors:  Tuanne Rotti Abrantes; Maria de Fátima Madeira; Denise Amaro da Silva; Carolina dos Santos F S Perié; Artur Augusto V Mendes Júnior; Rodrigo Caldas Menezes; Valmir Laurentino Silva; Fabiano Borges Figueiredo
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2016-02-23       Impact factor: 1.846

4.  Leishmania infection inhibits macrophage motility by altering F-actin dynamics and the expression of adhesion complex proteins.

Authors:  Juliana Perrone Bezerra de Menezes; Amrita Koushik; Satarupa Das; Can Guven; Ariel Siegel; Maria Fernanda Laranjeira-Silva; Wolfgang Losert; Norma W Andrews
Journal:  Cell Microbiol       Date:  2016-10-11       Impact factor: 3.715

Review 5.  Importance of nonenteric protozoan infections in immunocompromised people.

Authors:  J L N Barratt; J Harkness; D Marriott; J T Ellis; D Stark
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

6.  Association between skin parasitism and a granulomatous inflammatory pattern in canine visceral leishmaniosis.

Authors:  Washington L C dos-Santos; John David; Roberto Badaró; Luiz A R de-Freitas
Journal:  Parasitol Res       Date:  2003-11-11       Impact factor: 2.289

7.  Comparison of optical microscopy and quantitative polymerase chain reaction for estimating parasitaemia in patients with kala-azar and modelling infectiousness to the vector Lutzomyia longipalpis.

Authors:  Jailthon C Silva; Danielle A Zacarias; Vladimir C Silva; Nuno Rolão; Dorcas L Costa; Carlos Hn Costa
Journal:  Mem Inst Oswaldo Cruz       Date:  2016-07-18       Impact factor: 2.743

8.  The performance of serological tests for Leishmania infantum infection screening in dogs depends on the prevalence of the disease.

Authors:  Ivete Lopes de Mendonça; Joilson Ferreira Batista; Henk Schallig; Maria do Socorro Pires E Cruz; Diego Peres Alonso; Paulo Eduardo Martins Ribolla; Dorcas Lamounier Costa; Carlos Henrique Nery Costa
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2017-06-01       Impact factor: 1.846

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.